A 64-year-old man with type 2 diabetes, prior myocardial infarction and eGFR 48 mL/min/1.73 m² is on metformin and basal insulin. His HbA1c is 7.8%. According to updated Diabetes Canada recommendations, which additional antihyperglycaemic agent would best address his cardiovascular and renal risk?